We are live on
!
Find out more
SCM
Suvretta Capital Management Portfolio holdings
AUM
$3.92B
1-Year Est. Return
86.67%
This Fund
S&P 500
This Quarter
Est. Return
+19.42%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$1.87B
AUM Growth
-$497M
(-21%)
Cap. Flow
-$687M
Cap. Flow
% of AUM
-36.73%
Top 10 Holdings %
Top 10 Hldgs %
40.72%
Holding
114
New
19
Increased
26
Reduced
20
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Las Vegas Sands
LVS
|
+$40.5M |
| 2 |
Global Payments
GPN
|
+$28.9M |
| 3 |
NVIDIA
NVDA
|
+$25.7M |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$24.6M |
| 5 |
Zura Bio
ZURA
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$74.5M |
| 2 |
Elevance Health
ELV
|
+$70.3M |
| 3 |
Estee Lauder
EL
|
+$56.4M |
| 4 |
Colgate-Palmolive
CL
|
+$54.4M |
| 5 |
Yum! Brands
YUM
|
+$52.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.36% |
| 2 | Technology | 11.67% |
| 3 | Consumer Discretionary | 8.46% |
| 4 | Communication Services | 5.69% |
| 5 | Financials | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Royalty Pharma
RPRX
$26.1B
| $93.7M | 5.01% |
3,047,049
| – | – |
|
2
Biohaven
BHVN
$2.16B
| $92.5M | 4.95% |
3,867,558
+18,620
| +0.5% | +$321K |
|
|
ACLX
3
DELISTED
Arcellx
ACLX
| $90.1M | 4.82% |
2,848,167
+449,846
| +19% | +$17.2M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $81.6M | 4.36% |
793,355
-180,400
| -19% | -$19M |
|
|
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $75.9M | 4.06% |
1,198,971
| – | – |
|
6
Kura Oncology
KURA
$922M
| $74.4M | 3.98% |
7,028,442
+455,107
| +7% | +$5.38M |
|
7
Meta Platforms (Facebook)
META
$1.51T
| $72.1M | 3.85% |
251,230
-102,968
| -29% | -$25.4M |
|
|
KDNY
8
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $67.2M | 3.59% |
1,748,141
+179,344
| +11% | +$4.61M |
|
9
Insmed
INSM
$23.2B
| $65.6M | 3.51% |
3,109,334
+177,196
| +6% | +$3.36M |
|
|
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
| $48.7M | 2.6% |
5,561,835
+2,113,560
| +61% | +$24.6M |
|
|
ETNB
11
DELISTED
89bio
ETNB
| $45.4M | 2.42% |
2,393,236
+182,700
| +8% | +$3.21M |
|
|
MRNS
12
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $44.1M | 2.36% |
4,057,611
-773,650
| -16% | -$6.63M |
|
13
Amazon
AMZN
$2.5T
| $42.7M | 2.29% |
327,913
-231,577
| -41% | -$26.4M |
|
14
Advanced Micro Devices
AMD
$851B
| $42.2M | 2.26% |
370,607
-252,309
| -41% | -$26.2M |
|
|
15
Las Vegas Sands
LVS
$30.5B
| $39.7M | 2.13% |
+685,233
| New | +$40.5M |
|
16
Oracle
ORCL
$331B
| $37.9M | 2.03% |
318,425
-48,088
| -13% | -$4.97M |
|
17
ProKidney
PROK
$308M
| $35.7M | 1.91% |
3,193,175
| – | – |
|
|
18
NVIDIA
NVDA
$5.01T
| $32.8M | 1.75% |
+774,920
| New | +$25.7M |
|
19
Wynn Resorts
WYNN
$10.1B
| $31.5M | 1.69% |
298,658
-351,103
| -54% | -$37.6M |
|
20
EyePoint Inc
EYPT
$1.02B
| $29.8M | 1.59% |
3,423,897
+29,000
| +0.9% | +$177K |
|
|
XYZ
21
Block Inc
XYZ
$45.9B
| $28.8M | 1.54% |
432,296
+64,856
| +18% | +$4.05M |
|
|
22
Global Payments
GPN
$22.1B
| $27.7M | 1.48% |
+281,188
| New | +$28.9M |
|
23
RH
RH
$3.3B
| $27.4M | 1.47% |
+83,189
| New | +$21.7M |
|
24
Sutro Biopharma
STRO
$379M
| $27.4M | 1.46% |
588,369
+19,460
| +3% | +$969K |
|
25
Cogent Biosciences
COGT
$6.79B
| $26.3M | 1.41% |
2,219,693
+400,000
| +22% | +$4.59M |
|
Similar funds
MIM
AA
CCM
BCP
AS
MSI
FLSM
LWCA
Suvretta Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Suvretta Capital Management held 114 positions worth $1.87B, down 21% from $2.37B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Suvretta Capital Management withdrew a net $687M in Q2 2023, closing 14 positions and reducing 20 holdings. Its most notable exit was Estee Lauder, an estimated $56.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 47% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Suvretta Capital Management opened a new position in Las Vegas Sands worth $39.7M.
- Suvretta Capital Management's largest Q2 2023 buy was Las Vegas Sands: 685,233 shares worth $39.7M.
- Suvretta Capital Management added most to Terns Pharmaceuticals in Q2 2023, an estimated $24.6M increase.
- Suvretta Capital Management's biggest Q2 2023 reduction was UnitedHealth, cutting an estimated $74.5M.
- Suvretta Capital Management fully exited Estee Lauder in Q2 2023, selling an estimated $56.4M.
- Suvretta Capital Management's ten largest holdings make up 41% of its $1.87B portfolio in Q2 2023.
- Suvretta Capital Management opened 19 new positions and closed 14 in Q2 2023.
- Suvretta Capital Management's portfolio value fell 21% quarter-over-quarter to $1.87B.
Based on Suvretta Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.